A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

[1] Bladder cancer is usually stratified into two broad categories: papillary superficial and solid invasive tumors. Superficial tumors are the most frequent of all newly diagnosed bladder cancers ...